Pipradrol conditioned place preference is blocked by SCH23390

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Pipradrol is a stimulant drug with potential rewarding effects.
• Dopamine receptors, particularly D1 receptors, are implicated in reward pathways.
• Understanding the neurobiological underpinnings of pipradrol's effects is crucial.

Purpose of the Study:

• To investigate the role of the D1 dopamine receptor in mediating the rewarding effects of pipradrol.
• To determine if blocking D1 dopamine receptors prevents the establishment of pipradrol-conditioned place preference (CPP).

Main Methods:

• A conditioned place preference (CPP) paradigm was used in rodents.
• Various doses of pipradrol (6.25-75.0 mg/kg) were administered.
• The selective D1 dopamine antagonist SCH23390 (0.16 mg/kg) was administered to assess its effect on CPP establishment.

Main Results:

• Pipradrol successfully established a CPP at a dose of 25.0 mg/kg.
• Administration of SCH23390 blocked the establishment of the pipradrol-induced CPP.
• This blockade indicates that D1 dopamine receptor activation is necessary for pipradrol's rewarding effect.

Conclusions:

• Pipradrol exerts a rewarding effect that can be measured using the CPP paradigm.
• The findings strongly suggest that the rewarding effects of pipradrol are mediated, at least in part, by the activation of D1 dopamine receptors.
• This study highlights the critical role of the D1 dopamine system in mediating stimulant-induced reward.